1604 related articles for article (PubMed ID: 31215725)
1. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
Hashimoto K
Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.
Hashimoto K
Biochem Pharmacol; 2020 Jul; 177():113935. PubMed ID: 32224141
[TBL] [Abstract][Full Text] [Related]
3. An update on ketamine and its two enantiomers as rapid-acting antidepressants.
Zhang K; Hashimoto K
Expert Rev Neurother; 2019 Jan; 19(1):83-92. PubMed ID: 30513009
[No Abstract] [Full Text] [Related]
4. Arketamine, a new rapid-acting antidepressant: A historical review and future directions.
Zhang JC; Yao W; Hashimoto K
Neuropharmacology; 2022 Nov; 218():109219. PubMed ID: 35977629
[TBL] [Abstract][Full Text] [Related]
5. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Kishimoto T; Chawla JM; Hagi K; Zarate CA; Kane JM; Bauer M; Correll CU
Psychol Med; 2016 May; 46(7):1459-72. PubMed ID: 26867988
[TBL] [Abstract][Full Text] [Related]
6. A historical review of antidepressant effects of ketamine and its enantiomers.
Wei Y; Chang L; Hashimoto K
Pharmacol Biochem Behav; 2020 Mar; 190():172870. PubMed ID: 32035078
[TBL] [Abstract][Full Text] [Related]
7. AMPA Receptor Activation-Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine.
Yang C; Kobayashi S; Nakao K; Dong C; Han M; Qu Y; Ren Q; Zhang JC; Ma M; Toki H; Yamaguchi JI; Chaki S; Shirayama Y; Nakazawa K; Manabe T; Hashimoto K
Biol Psychiatry; 2018 Oct; 84(8):591-600. PubMed ID: 29945718
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.
Wei Y; Chang L; Hashimoto K
Mol Psychiatry; 2022 Jan; 27(1):559-573. PubMed ID: 33963284
[TBL] [Abstract][Full Text] [Related]
9. Ketamine's antidepressant action: beyond NMDA receptor inhibition.
Hashimoto K
Expert Opin Ther Targets; 2016 Nov; 20(11):1389-1392. PubMed ID: 27646666
[TBL] [Abstract][Full Text] [Related]
10. KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.
Abdallah CG; Adams TG; Kelmendi B; Esterlis I; Sanacora G; Krystal JH
Depress Anxiety; 2016 Aug; 33(8):689-97. PubMed ID: 27062302
[TBL] [Abstract][Full Text] [Related]
11. Arketamine for cognitive impairment in psychiatric disorders.
Hashimoto K
Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1513-1525. PubMed ID: 36786865
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacology of ketamine and esketamine as rapid-acting antidepressants].
Pavlidi P; Megalokonomou A; Sofron A; Kokras N; Dalla C
Psychiatriki; 2021 Dec; 32(Supplement I):55-63. PubMed ID: 34990380
[TBL] [Abstract][Full Text] [Related]
13. Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.
Kadriu B; Musazzi L; Henter ID; Graves M; Popoli M; Zarate CA
Int J Neuropsychopharmacol; 2019 Feb; 22(2):119-135. PubMed ID: 30445512
[TBL] [Abstract][Full Text] [Related]
14. How does ketamine elicit a rapid antidepressant response?
Kavalali ET; Monteggia LM
Curr Opin Pharmacol; 2015 Feb; 20():35-9. PubMed ID: 25462290
[TBL] [Abstract][Full Text] [Related]
15. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
16. An update on NMDA antagonists in depression.
Pochwat B; Nowak G; Szewczyk B
Expert Rev Neurother; 2019 Nov; 19(11):1055-1067. PubMed ID: 31328587
[No Abstract] [Full Text] [Related]
17. NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
Zanos P; Moaddel R; Morris PJ; Georgiou P; Fischell J; Elmer GI; Alkondon M; Yuan P; Pribut HJ; Singh NS; Dossou KS; Fang Y; Huang XP; Mayo CL; Wainer IW; Albuquerque EX; Thompson SM; Thomas CJ; Zarate CA; Gould TD
Nature; 2016 May; 533(7604):481-6. PubMed ID: 27144355
[TBL] [Abstract][Full Text] [Related]
18. Targeting glutamate signalling in depression: progress and prospects.
Murrough JW; Abdallah CG; Mathew SJ
Nat Rev Drug Discov; 2017 Jul; 16(7):472-486. PubMed ID: 28303025
[TBL] [Abstract][Full Text] [Related]
19. (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression.
Yokoyama R; Higuchi M; Tanabe W; Tsukada S; Naito M; Yamaguchi T; Chen L; Kasai A; Seiriki K; Nakazawa T; Nakagawa S; Hashimoto K; Hashimoto H; Ago Y
Pharmacol Biochem Behav; 2020 Apr; 191():172876. PubMed ID: 32088360
[TBL] [Abstract][Full Text] [Related]
20. Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites.
Yang C; Yang J; Luo A; Hashimoto K
Transl Psychiatry; 2019 Nov; 9(1):280. PubMed ID: 31699965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
